completes

  1. T

    Impax Pharmaceuticals Completes Enrollment In APEX-PD Phase III Trial Of IPX066 In Pa

    Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease...
  2. T

    Boston Scientific Completes Enrollment In PLATINUM Trials For Small Vessels And Long

    Boston Scientific Corporation (NYSE: BSX) announced the completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program. The trials are designed to compare the platinum chromium PROMUS® Element™ Everolimus-Eluting Stent System to matched historical...
  3. T

    Arcadia Biosciences Completes First Commercial Production Of SONOVA™ 400 High GLA Saf

    Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the first commercial production of SONOVA™ 400 High GLA Safflower Oil. Seed produced by...
  4. G

    Symbian completes open source migration project

    The Symbian Foundation offers free code to everyone to enable them to contribute openly to the future of mobile.
  5. T

    China Pharma Holdings, Inc. Completes Clinical Trials For Candesartan Anti-Hypertensi

    China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production...
  6. T

    China Pharma Holdings, Inc. Completes Clinical Trials For Candesartan Anti-Hypertensi

    China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production...
Back
Top